This article is for informational and educational purposes only and does not constitute medical advice. Ovagen is supplied by Wholesale Peps as lyophilized research-grade material for in vitro laboratory use only and is not approved by the FDA for human or veterinary use.
Ovagen is a synthetic tripeptide composed of glutamic acid, aspartic acid, and leucine (Glu-Asp-Leu; single-letter: EDL), developed by the research group of Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the peptide bioregulator class — a series of short synthetic peptides proposed to modulate gene expression in a tissue-specific manner by interacting with DNA regulatory elements. Ovagen was characterized within the Khavinson series as a bioregulator for hepatic (liver) tissue, with additional interest in gastrointestinal epithelium. Cell-based and organotypic tissue-culture studies, conducted predominantly within the Khavinson laboratory, have examined associations between EDL exposure and markers of hepatocyte proliferation, tissue renewal, and gene expression relevant to liver function and aging. Molecular docking analyses have additionally examined EDL’s proposed interactions with gene promoter sequences. No peer-reviewed clinical trials evaluating Ovagen in human subjects have been published; all available mechanistic and pharmacological evidence derives from cell-based assays, organotypic cultures, animal studies, and in silico analyses.
1. Background
1.1 Peptide Bioregulators — The Khavinson Class
The peptide bioregulator concept was developed in the Soviet Union and later Russia beginning in the 1970s by Vladimir Khavinson and colleagues at the Institute of Bioregulation and Gerontology in St. Petersburg. The foundational hypothesis holds that short peptides (typically 2–4 amino acids) derived from or modeled on organ-specific tissue extracts can regulate gene expression in a tissue-targeted manner, with proposed applications in aging biology and age-related disease.
The class includes a range of named compounds, each proposed to target specific tissue types: Epitalon (Ala-Glu-Asp-Gly) for the pineal gland, Bronchogen (Ala-Glu-Asp-Leu) for bronchial tissue, Livagen (Lys-Glu-Asp-Ala) for hepatic tissue, and Ovagen (Glu-Asp-Leu) also for hepatic and gastrointestinal tissue, among others. Notably, Ovagen’s EDL sequence is identical to the C-terminal three residues of Bronchogen (AEDL), differing only by the absence of the N-terminal alanine — yet the two are assigned to different target tissues, which illustrates the unresolved question of how sequence maps to tissue specificity in this class. The biological rationale for tissue specificity — why a tripeptide would preferentially influence gene expression in one tissue over another following systemic administration — has not been mechanistically established through independent research [2].
1.2 The Liver, Regeneration, and Digestive Tissue
The liver is the body’s primary metabolic organ, responsible for detoxification, protein synthesis, bile production, and the metabolism of nutrients and xenobiotics. It is also unique among adult organs for its substantial regenerative capacity: hepatocytes, which are normally quiescent, can re-enter the cell cycle to restore liver mass after injury or partial loss [4]. Liver function and regenerative capacity decline with age, and the organ is continuously exposed to oxidative and metabolic stress. The gastrointestinal epithelium, likewise, undergoes continuous renewal and barrier maintenance.
Ovagen’s development within the Khavinson group was based on the hypothesis that a short peptide modeled on liver tissue-derived sequences could support gene expression programs relevant to hepatocyte function, tissue renewal, and resistance to metabolic and oxidative stress, with additional interest in gastrointestinal epithelial tissue. The specific relationship between the EDL sequence and endogenous hepatic peptide content has not been independently characterized.
1.3 Historical and Research Context
The Khavinson group has published extensively on peptide bioregulators since the 1970s, accumulating a substantial body of literature in Russian-language and international journals, including organotypic tissue-culture studies of short peptides conducted with N. I. Chalisova and colleagues [3]. The vast majority of research on Ovagen and related peptide bioregulators originates from this single research group. Independent replication of key findings by laboratories outside the Khavinson group is limited, which is a primary consideration when evaluating the available literature [1].
2. Molecular Structure
Ovagen is a tripeptide with the sequence Glu-Asp-Leu, abbreviated in single-letter code as EDL. At three residues it is among the shortest peptides in the research peptide class, alongside Pinealon (EDR), Chonluten (EDG), and Cartalax (AED).
| Property | Detail |
|---|---|
| Full name | L-α-Glutamyl-L-α-aspartyl-L-leucine |
| Sequence (single-letter) | EDL |
| Length | 3 amino acids (tripeptide) |
| Molecular formula | C₁₅H₂₅N₃O₈ |
| Molecular weight | ~375 Da |
| Net charge (physiological pH) | Acidic: two acidic residues (Glu, Asp) and one hydrophobic (Leu) |
| Relationship to Bronchogen | Identical to the C-terminal tripeptide of Bronchogen (AEDL) |
| Post-translational modifications | None; fully synthetic |
| Water solubility | Moderate to high |
| Class | Peptide bioregulator (Khavinson group) |
Unlike Pinealon (EDR), which carries a basic arginine at its C-terminus, or Chonluten (EDG), which terminates in glycine, Ovagen terminates in leucine — a hydrophobic, branched-chain amino acid. The molecule carries a net negative charge at physiological pH from its two acidic residues, while the leucine side chain contributes hydrophobic character that has been proposed to influence membrane interaction. In the Khavinson group’s proposed DNA-binding framework, the acidic glutamate and aspartate side chains are proposed to participate in sequence-specific contacts. Whether the EDL tripeptide interacts with genomic DNA in the manner proposed — and whether such interaction, if it occurs, is sufficient to alter transcription at physiologically meaningful concentrations — has not been independently established [2].
3. Proposed Mechanisms
The mechanisms below have been proposed in cell-based, organotypic culture, animal model, and computational studies. None has been confirmed in controlled human interventional research. All mechanistic claims originate predominantly from the Khavinson group.
4. Key Research Findings
| Research Area | Evidence Level | Best Available Evidence |
|---|---|---|
| Hepatocyte proliferation / tissue renewal | Limited Cell-based / organotypic |
Khavinson & Chalisova group; tissue-culture studies |
| DNA interaction / gene expression | Limited In silico + cell-based |
Tarnovskaya et al. 2014 (Adv Gerontol) |
| Chromatin regulation / antioxidant | Limited Cell-based only |
Khavinson group; multiple studies |
| Gastrointestinal epithelium | Limited Cell-based only |
Limited published literature |
| Hepatic function (in vivo / animal) | Limited Khavinson group only |
Limited; predominantly originating laboratory |
| Human clinical evidence | Limited None published |
No peer-reviewed trials identified |
4.1 Hepatic Tissue and Organotypic Culture Studies
Research within the Khavinson group, including organotypic tissue-culture work conducted with Chalisova and colleagues, has reported that short peptides including EDL were associated with increased indices of cell proliferation and renewal in tissue preparations relative to untreated controls, an effect described as more pronounced in tissue from aged donors [3]. These cell-based and tissue-culture findings represent the primary experimental basis for Ovagen’s proposed role in supporting hepatic regenerative capacity. The specific effect magnitudes and experimental conditions have not been fully characterized in peer-reviewed literature accessible through international databases.
Schematic representation based on approximate directional findings reported for short peptides in organotypic tissue-culture models [3]. Values are illustrative approximations and should not be interpreted as precise experimental data. Not derived from human or in vivo studies.
4.2 DNA Interaction and Gene Regulatory Mechanism
Tarnovskaya et al. (2014) described the mechanistic framework by which short bioregulator peptides are proposed to interact with DNA. Using molecular modeling and docking analyses, the group proposed that short peptides bind to specific nucleotide sequences in promoter regions of target genes, with charged residues forming electrostatic contacts with the DNA phosphate backbone and side chains participating in sequence-specific interactions within the major groove [2]. For EDL, the two acidic residues are proposed to contribute sequence-specific contacts, while the hydrophobic leucine side chain has been proposed to influence interaction with the nuclear membrane and local hydrophobic environment.
Different short peptide sequences were reported to show preferential in silico affinity for different DNA nucleotide motifs, providing the proposed theoretical basis for tissue-specific gene regulation by different named bioregulators. The applicability of these in silico binding affinities to transcriptional regulation in living cells — where peptides must compete with histones, transcription factors, and other DNA-binding proteins at far higher effective concentrations — has not been independently verified by structural or biochemical methods such as ChIP, EMSA, or DNase I footprinting.
4.3 Ovagen, Livagen, and the Tissue-Specificity Question
Ovagen (EDL) is not the only Khavinson bioregulator associated with the liver: Livagen (Lys-Glu-Asp-Ala, KEDA) is also classified as a hepatic peptide, and the two carry different sequences. At the same time, Ovagen’s EDL sequence is identical to the C-terminal tripeptide of Bronchogen (AEDL), which is assigned to bronchial rather than hepatic tissue. This pattern — distinct sequences sharing a target tissue, and shared sequence motifs spanning different target tissues — highlights the central unresolved question of the bioregulator hypothesis: the molecular basis by which a given short peptide would exert tissue-preferential effects has not been established in the independent literature [2].
5. Evidence Status
| Evidence Type | Current Status |
|---|---|
| In silico / molecular docking studies | Published (Khavinson group; multiple papers) |
| Cell-based / organotypic tissue-culture studies | Published (Khavinson & Chalisova group; predominantly Russian-language journals) |
| Animal model studies (hepatic / gastrointestinal) | Limited; predominantly from the Khavinson laboratory |
| Independent replication of key findings | Not identified; research predominantly from a single group |
| Phase 1 human safety and pharmacokinetic trial | Not published |
| Phase 2 / Phase 3 efficacy trial | Not published |
| Regulatory submission or approval | Not applicable; no IND-stage development reported internationally |
What We Still Don’t Know
- Whether the proposed DNA-binding mechanism operates in living cells: The in silico docking analyses propose a specific interaction between EDL and gene promoter sequences, but whether this peptide at pharmacologically achievable intracellular concentrations actually binds chromatin-associated DNA in intact hepatic or gastrointestinal cells has not been demonstrated by independent investigators using established biochemical methods.
- Whether tissue specificity exists and how it would operate: The classification of Ovagen as a hepatic bioregulator implies tissue-preferential activity. No published pharmacokinetic study has demonstrated preferential distribution of EDL to liver or gastrointestinal tissue relative to other tissues following systemic administration — a question made sharper by the sequence overlap with the bronchial peptide Bronchogen.
- Whether the marker-level effects translate to function: Reported changes in hepatocyte proliferation indices and gene expression markers are marker-level observations in cultured cells and organotypic preparations. Whether they correspond to any meaningful change in liver or gastrointestinal function in a whole organism is unknown.
- How Ovagen relates to Livagen: Both EDL (Ovagen) and KEDA (Livagen) are classified as hepatic bioregulators, but whether they act through overlapping or distinct pathways, and whether either offers any advantage, has not been clarified in the independent literature.
- Human safety and pharmacokinetics: No published phase 1 trial characterizes the safety, tolerability, half-life, or target-tissue distribution of Ovagen in humans. As a tripeptide, it would be expected to undergo rapid hydrolysis by plasma and tissue peptidases, but human pharmacokinetic data are absent.
- Effective dose and route of administration in any in vivo context: Dose-response data in animal models and the pharmacologically active concentration range in living hepatic or gastrointestinal tissue are not characterized in the independent literature.
6. Limitations of Current Research
References
- Khavinson VKh, Malinin VV. Gerontological Aspects of Genome Peptide Regulation. Basel: Karger; 2005. ISBN 3-8055-7833-7.
- Tarnovskaya SI, Khavinson VKh, Linkova NS, Pronyaeva VE, Kolchina NV, Tendler SM. “Mechanism of Short Peptides Interaction with DNA.” Advances in Gerontology. 2014;27(4):706–714.
- Chalisova NI, Linkova NS, Zhekalov AN, Orlova AO, Ryzhak GA, Khavinson VKh. “Short peptides stimulate cell renewal in organotypic tissue cultures during aging.” Advances in Gerontology. 2015;5(3):176–181. doi:10.1134/S2079057015030029
- Michalopoulos GK. “Liver regeneration.” Journal of Cellular Physiology. 2007;213(2):286–300. doi:10.1002/jcp.21172